MedTrace Logo

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00090727 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2006-11-02

No results posted yet for this study

Summary

The purposes of this study are to determine:

* the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle
* the side effects of AQ4N when given on the above schedule
* how much AQ4N is in the blood and urine at specific times after administration and how the body get rids of AQ4N
* if AQ4N helps treat cancer

Conditions

  • Solid Malignancies
  • Non-Hodgkin's Lymphoma

Interventions

DRUG

AQ4N

Sponsors & Collaborators

  • Novacea

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00090727 on ClinicalTrials.gov